Figma Shares Indicated To Open $105/$110
ACTON, Mass. - Insulet Corporation (NASDAQ:PODD) reported fourth-quarter earnings and revenue that surpassed analyst expectations, driven by robust demand for its Omnipod insulin pump products. The company also provided an optimistic outlook for 2025.
The tubeless insulin pump technology leader posted adjusted earnings per share of $1.15, exceeding the analyst estimate of $1.03. Revenue for the quarter came in at $597.5 million, topping the consensus estimate of $582.7 million and representing a 17.2% increase YoY.
Total (EPA:TTEF) Omnipod revenue grew 16.9% to $585.7 million, with U.S. Omnipod revenue rising 12.4% to $443.7 million and International Omnipod revenue surging 33.5% to $142.0 million.
Insulet’s stock edged up 0.6% following the earnings release, indicating a mildly positive investor response to the results.
For the full year 2024, Insulet reported revenue of $2.1 billion, up 22.1% YoY, marking the first time the company has surpassed $2 billion in annual revenue.
Looking ahead, Insulet provided a strong outlook for 2025, projecting total revenue growth of 16% to 20% in constant currency. The company expects U.S. Omnipod revenue to grow 16% to 20% and International Omnipod revenue to increase 22% to 26%.
"We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and CEO.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.